ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

Trial to investigate the safety and efficacy of ARM210 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

Related Keywords

United States ,Netherlands ,Amsterdam ,Noord Holland ,Danielle Ellis ,Pharma Inc ,Amsterdam University Medical Center ,Mayo Clinic ,Ryanodine Receptor ,Related Myopathy ,Gene Marcantonio ,Chief Executive Officer ,